                </a></li></ul></div><p><strong>Figure 8.  <span>Protease Inhibitor-Resistant HIV-1 with Impaired CA-SP1 Cleavage Is Hypersensitive to Bevirimat In Vitro.</span></strong></p><a id="article1.body1.sec3.sec5.fig2.caption1.p1" name="article1.body1.sec3.sec5.fig2.caption1.p1"></a><p>NL4-3 PR<sub>I54V+V82A</sub> is hypersensitive to bevirimat in PHA-activated PBMCs with 50% inhibitory concentration (IC<sub>50</sub>) &gt;100 times lower than for wild-type NL4-3. CC<sub>50</sub> is the 50% cytotoxic concentration as assessed by MTT assay.</p>
<span>THISISTHEEND
